C-Crest trial data on new Merck coformulation. This is one to watch in the future. We need to pay attention to the Phase 3 results and trial opportunities.
Efficacy and Safety of the Fixed-Dose Combination Regimen of Grazoprevir/Ruzasvir/Uprifosbuvir (MK-3682) With or Without Ribavirin in Non-cirrhotic or Cirrhotic Participants With Chronic HCV GT1, 2, 3, 4, or 6 Infection (Parts A & B of C-CREST-1 & 2)
C-Crest trial data on new Merck coformulation. This is one to watch in the future. We need to pay attention to the Phase 3 results and trial opportunities.
C-CREST DATA
Coming Phase 3 Trials/EU (Scroll down)